UniQure NV

Overview

UniQure NV (UniQure) develops and markets gene therapy products. The company develops adeno-associated virus (AAV) based gene therapies using its gene technology platform and offers disease-modifying treatments to patients with severe genetic diseases and other devastating diseases. UniQure’s lead product, AMT-060 is a gene therapy for treatment of moderately-severe hemophilia B. It preclinical product include AMT-130, an AAV5 vector for the treatment of Huntington's disease and AMT-150 for Spinocerebellar Ataxia type 3. The company develops a gene platform to bring new disease modifying therapies to patients with genetic diseases. The company conducts drug discovery and preclinical research in collaboration with academic research institutions. UniQure is headquartered in Amsterdam, North Holland, the Netherlands.
Key Stats
Address
Paasheuvelweg 25a, AMSTERDAM, 1105 BP, Netherlands
Headquarters

Netherlands

Contact

31 20 2406000

Website
www.uniqure.com
No of Employees

332

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

QURE [NASD]

Revenue (2020)

$38 m

422% (2020 vs 2019)
Net Income (2020)

$-125 m

-0.6% (2020 vs 2019)
Net Profit Margin

-333 %

80.5% (2020 vs 2019)
Market Cap *

$1,598 m

EPS *

$-2.8

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters UniQure NVBioMarin Pharmaceutical Incbluebird bio IncApplied Genetic Technologies Corp
Key Information
Headquarters Netherlands United States of America United States of America United States of America
Headquarter City AMSTERDAM NOVATO CAMBRIDGE ALACHUA
Headquarter State/Province - California Massachusetts Florida
No. of Employees 332 3,059 1,213 83
Entity Type Public Public Public Public

Products & Services

UniQure offers gene therapy products. Key products and services offered by the company include the following:

Products
  • Pipeline
  • Liver Directed Diseases:
  • Etranacogene dezaparvovec (AMT-060/061)
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Pierre Caloz Chief Operations Officer Senior Management 2021 - Mr. Pierre Caloz has been the Chief Operations Officer of the company since 2021. Most recently, he served as Senior...
Maria E. Cantor Chief Communications Officer Senior Management 2020 - Ms. Maria E. Cantor has been the Chief Communication Officer of the company since September 2020. Previously, she served as...
James Brady Chief Human Resources Officer Senior Management 2020 - Mr. James Brady has been the Chief Human Resources Officer of the company since August 2020. Previously, he served at...
David Cerveny Chief Legal Officer; General Counsel; Secretary Senior Management 2018 - Mr. David Cerveny has been the Chief Legal Officer, General Counsel and Secretary of the company since March 2018. Prior...
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2021 Contracts/Agreements In May, the review of the agreement with CSL Behring under antitrust laws in the…
2021 Contracts/Agreements In June, the company entered into an agreement to acquire Corlieve Therapeutics, a biotechnology company.
2020 Contracts/Agreements In March, UniQure and Gen-X signed an exclusive research collaboration and license agreement to identify…
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2019 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2018 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


UniQure IP BV

Address

Meibergdreef 61, 1100 DA Amsterdam Zuidoost, Amsterdam
Netherlands

Telephone

31 20 566739

Website

www.amtbv.com
UniQure GmbH

Address

Im Neuenheimer Feld 410, Heidelberg
Germany

Telephone

49 6221 5638673

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
22 Jun 2021 uniQure to Acquire Corlieve Therapeutics Acquisition UniQure NV Corlieve Therapeutics SAS
01 Mar 2021 uniQure to Raise up to USD200 Million in Public Offering of Shares Equity Offering UniQure NV
24 Jun 2020 CSL Behring Enters into Licensing Agreement with uniQure Licensing Agreement CSL Behring LLC UniQure NV
02 Mar 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
02 Mar 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
04 Sep 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

7

Active Jobs

0

Posted

0

Closed

Job Trends

Latest Jobs

Job title Company Country
Lead Validation Engineer UniQure NV United States
Director, Program Management UniQure NV United States
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar